DETECTING CANCER DRIVER GENES AND PATHWAYS

(19)

(11)

EP 3 443 118 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	14.02.2024 Bulletin 2024/07

(45)	Mention of the grant of the patent:
	10.01.2024 Bulletin 2024/02

(21)	Application number: 17733112.1

(22)	Date of filing: 14.04.2017

(51)

International Patent Classification (IPC):

C12Q 1/68^(2018.01)

(52)	Cooperative Patent Classification (CPC):
	C12Q 1/6869; G16B 20/00

	C-Sets:
	C12Q 1/6869, C12Q 2537/165;

(86)	International application number:
	PCT/US2017/027794

(87)	International publication number:
	WO 2017/181134 (19.10.2017 Gazette 2017/42)

(54)	DETECTING CANCER DRIVER GENES AND PATHWAYS NACHWEIS VON KREBSSTEUERNDEN GENEN UND SIGNALWEGEN DÉTECTION DE GÈNES VECTEURS DE CANCERS ET DE VOIES DE SIGNALISATION ASSOCIÉES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

15.04.2016 US 201662323535 P

(43)	Date of publication of application:
	20.02.2019 Bulletin 2019/08

(73)	Proprietors:
	F. Hoffmann-La Roche AG 4070 Basel (CH) Designated Contracting States: AL AT BE BG CH CY CZ DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Roche Diagnostics GmbH 68305 Mannheim (DE) Designated Contracting States: DE

(72)	Inventors:
	FU, Yao San Mateo California 94403 (US) CHHIBBER, Aparna San Mateo California 94401 (US) MOHIYUDDIN, Marghoob Foster City California 94404 (US) FANG, Li Tai San Francisco California 94122 (US) LAM, Hugo Y.K. Sunnyvale California 94087 (US)

(74)	Representative: Burger, Alexander et al
	Roche Diagnostics GmbH Patentabteilung Nonnenwald 2 82377 Penzberg 82377 Penzberg (DE)

(56)

References cited: :

CN-A- 103 305 625

KR-A- 20150 102 468

A. YOUN ET AL: "Identifying cancer driver genes in tumor genome sequencing studies", BIOINFORMATICS, vol. 27, no. 2, 17 December 2010 (2010-12-17), pages 175-181, XP055155001, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btq630 cited in the application
COLLIN J. TOKHEIM ET AL: "Evaluating the evaluation of cancer driver genes", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 113, no. 50, 22 November 2016 (2016-11-22), pages 14330-14335, XP055406786, US ISSN: 0027-8424, DOI: 10.1073/pnas.1616440113
XIUYING XIAO ET AL: "Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, vol. 11, no. 1, 20 June 2013 (2013-06-20), page 151, XP021155521, ISSN: 1479-5876, DOI: 10.1186/1479-5876-11-151
K. D. KORTHAUER ET AL: "MADGiC: a model-based approach for identifying driver genes in cancer", BIOINFORMATICS, vol. 31, no. 10, 15 May 2015 (2015-05-15), pages 1526-1535, XP055217196, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btu858

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).